The latest announcement is out from DKSH Holding AG ( (CH:DKSH) ).
DKSH has signed an agreement to acquire Molecular Diagnostics Korea Inc. (MDxK), a prominent player in the South Korean life-science market, to strengthen its position in the molecular diagnostics sector. This acquisition is expected to enhance DKSH’s scientific solutions business in Asia, leveraging MDxK’s expertise and existing client relationships to meet the rising demand for advanced scientific solutions in South Korea.
More about DKSH Holding AG
DKSH is a leading Market Expansion Services provider with a focus on Asia, offering services in Healthcare, Consumer Goods, Performance Materials, and Technology. The company provides sourcing, market insights, marketing and sales, eCommerce, distribution and logistics, and after-sales services. DKSH operates in 36 markets with 28,060 specialists and generated net sales of CHF 11.1 billion in 2024.
YTD Price Performance: 8.77%
Average Trading Volume: 72,278
Technical Sentiment Signal: Sell
Current Market Cap: CHF4.76B
See more insights into DKSH stock on TipRanks’ Stock Analysis page.